<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37730538</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-230X</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>BMC gastroenterology</Title><ISOAbbreviation>BMC Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Clinical manifestation, staging and prognosis of hepatocellular carcinoma in Gambian patients.</ArticleTitle><Pagination><StartPage>321</StartPage><MedlinePgn>321</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12876-023-02952-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As a result of the lack of screening programs and the difficulty in making a proper diagnosis, the majority of hepatocellular carcinoma (HHC) patients present late in low-resource countries. The study therefore assesses the clinical features, stage and prognostic variables of patients with HCC in The Gambia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From December 2015 to January 2019, patients with a confirmed diagnosis of HCC were enrolled. All patients' medical history, ultrasound scan, FibroScan and laboratory details were collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two hundred and sixty (260) patients were enrolled. The mean age of HCC patients was 40 years, and 210 (80.7%) of them were male. The most common gastrointestinal symptoms were early satiety 229 (88.1%) and abdominal pain 288 (87.7%), while the most common constitutional symptoms were weight loss 237 (91.2%) and easy fatiguability 237 (91.2%). Hepatomegaly 205 (78.8%) was the most common sign. On ultrasound scan, lesions were mostly multifocal 175 (67.3%), and the median FibroScan score was 75&#xa0;kPa. The median fibrosis 4 and aspartate transferase platelet ratio index were 4.6 and 2.2, respectively. Hepatitis B surface antigen (HBsAg) was positive in 170 (65.4%) patients, and the median AFP level was 3263 ng/ml. HCC patients with positive HBsAg were more likely to be male 145 (85.3%) vs 62 (72.1%) (p&#x2009;=&#x2009;0.011), much younger 39.9 vs 51.4 yrs (p&#x2009;=&#x2009;&#x2009;&lt;&#x2009;0.0001), more likely to have abdominal pain 156 (91.8%) vs 68 (79.1%) (p&#x2009;=&#x2009;0.002), jaundice 78 (45.9%) vs 29 (33.7%) (p&#x2009;=&#x2009;0.042), dark urine 117 (68.8%) vs 46 (53.5%) (p&#x2009;=&#x2009;0.018), raised transaminases (Aspartate transaminases 224.5 (32-7886) vs 153 (18-610), p&#x2009;=&#x2009;&#x2009;&lt;&#x2009;0.01, Alanine transferases 71 (5-937) vs 47 (8-271), p&#x2009;=&#x2009;&#x2009;&lt;&#x2009;0.001) and decreased platelet count 207 (33-941) vs 252 (52- 641) (p&#x2009;=&#x2009;0.021) compared to patients with HCC who were HBsAg-negative.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The prognosis of patients with HCC is poor in developing countries such as The Gambia, where screening programs and treatment modalities are scarce. Young males are disproportionately affected, and HBV is a major cause of HCC in The Gambia.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bittaye</LastName><ForeName>Sheikh Omar</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Edward Francis Small Teaching Hospital, Banjul, The Gambia. sobittaye@utg.edu.gm.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine and Allied Health Sciences, University of The Gambia, Banjul, The Gambia. sobittaye@utg.edu.gm.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kambi</LastName><ForeName>Abubacarr</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Edward Francis Small Teaching Hospital, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tekanyi</LastName><ForeName>Momodou A I</ForeName><Initials>MAI</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Edward Francis Small Teaching Hospital, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamba</LastName><ForeName>Saydiba</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Edward Francis Small Teaching Hospital, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanneh</LastName><ForeName>Lamin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Disease Control &amp; Elimination, MRC Unit The Gambia @ London School of Hygiene &amp; Tropical Medicine, Fajara, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sisawo</LastName><ForeName>Momodou Musa</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Disease Control &amp; Elimination, MRC Unit The Gambia @ London School of Hygiene &amp; Tropical Medicine, Fajara, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jatta</LastName><ForeName>Abdoulie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Disease Control &amp; Elimination, MRC Unit The Gambia @ London School of Hygiene &amp; Tropical Medicine, Fajara, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fatty</LastName><ForeName>Gibril</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Disease Control &amp; Elimination, MRC Unit The Gambia @ London School of Hygiene &amp; Tropical Medicine, Fajara, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeng</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Disease Control &amp; Elimination, MRC Unit The Gambia @ London School of Hygiene &amp; Tropical Medicine, Fajara, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jallow</LastName><ForeName>Momodou Salieu</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>School of Medicine and Allied Health Sciences, University of The Gambia, Banjul, The Gambia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathology Department, Edward Francis Small Teaching Hospital, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leigh</LastName><ForeName>Ousman</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>School of Medicine and Allied Health Sciences, University of The Gambia, Banjul, The Gambia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathology Department, Edward Francis Small Teaching Hospital, Banjul, The Gambia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>American International University, Serekunda, Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Njie</LastName><ForeName>Ramou</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Edward Francis Small Teaching Hospital, Banjul, The Gambia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine and Allied Health Sciences, University of The Gambia, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Gastroenterol</MedlineTA><NlmUniqueID>100968547</NlmUniqueID><ISSNLinking>1471-230X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Carcinoma</Keyword><Keyword MajorTopicYN="N">Hepatitis B</Keyword><Keyword MajorTopicYN="N">Hepatocellular</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>20</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37730538</ArticleId><ArticleId IdType="doi">10.1186/s12876-023-02952-8</ArticleId><ArticleId IdType="pii">10.1186/s12876-023-02952-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020&#x202f;: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA A Cancer J Clin. 2021;71:209&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukthinuthalapati VVPK, Sewram V, Ndlovu N, Kimani S, Abdelaziz AO, Chiao EY, et al. Hepatocellular carcinoma in Sub-Saharan Africa. JCO Global Oncol. 2021;7:756&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/GO.20.00425</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JD, Lewis RR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2014;24:899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2010.07.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Amponsah-dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? World J Gastroenterol. 2021;27:6025&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v27.i36.6025</ArticleId><ArticleId IdType="pubmed">34629817</ArticleId><ArticleId IdType="pmc">8476331</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer. 2008;127:2893&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.25516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladep NG, Lesi OA, Mark P, Lemoine M, Onyekwere C, Afihene M, et al. Problem of hepatocellular carcinoma in West Africa. World J HepatoL. 2014;6:783&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="doi">10.4254/wjh.v6.i11.783</ArticleId><ArticleId IdType="pubmed">25429316</ArticleId><ArticleId IdType="pmc">4243152</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaquet A, Tchounga B, Tanon A, Bagny A, Didier K, Traore HA, et al. Etiology of hepatocellular carcinoma in West Africa, a case-control study. Int J Cancer. 2018;143(4):869&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.31393</ArticleId><ArticleId IdType="pubmed">29569722</ArticleId><ArticleId IdType="pmc">6041181</ArticleId></ArticleIdList></Reference><Reference><Citation>El-serag HB. Hepatocellular Carcinoma. N Engl J Med. 2011;365:1118&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1001683</ArticleId><ArticleId IdType="pubmed">21992124</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)61412-X</ArticleId><ArticleId IdType="pubmed">26231459</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemoine M, Shimakawa Y, Njie R, Taal M, Ndow G, Chemin I, et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia&#x202f;: the Prevention of Liver Fibrosis and Cancer in Africa ( PROLIFICA ) study. Lancet Glob Heal. 2011;4:e559&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(16)30130-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung TK, Lai CL, Wong BCY, Fung J, Yuen MF. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther. 2006;24:573&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2006.03029.x</ArticleId><ArticleId IdType="pubmed">16907890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew MC. Hepatocellular carcinoma in developing countries&#x202f;: prevention, diagnosis and treatment. World J Hepatol. 2012;4:99&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="doi">10.4254/wjh.v4.i3.99</ArticleId><ArticleId IdType="pubmed">22489262</ArticleId><ArticleId IdType="pmc">3321496</ArticleId></ArticleIdList></Reference><Reference><Citation>Viviani S, Carrieri P, Bah E, Hall AJ, Kirk GD, Mendy M, et al. 20 Years into the Gambia hepatitis intervention study&#x202f;: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:3216&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-08-0303</ArticleId><ArticleId IdType="pubmed">18990765</ArticleId></ArticleIdList></Reference><Reference><Citation>Bah E, Carrieri MP, Hainaut P, Bah Y, Nyan O, Taal M. 20-years of population-based cancer registration in hepatitis b and liver cancer prevention in The Gambia. West Africa PLoS One. 2013;8:1&#x2013;11.</Citation></Reference><Reference><Citation>Kirk G, Lesi O, Mendy M, Akano A, Sam O, Goedert J, et al. The Gambia liver cancer study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology. 2004;39:211&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.20027</ArticleId><ArticleId IdType="pubmed">14752840</ArticleId></ArticleIdList></Reference><Reference><Citation>Manieri E, Herrera-melle L, Mora A, Tom A, Leiva-vega L, Fern DI, et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J Exp Med. 2019;216:1108&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20181288</ArticleId><ArticleId IdType="pubmed">30944152</ArticleId><ArticleId IdType="pmc">6504215</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng B, Zhu YJ, Wang HY, Chen L. Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms. Sci China Life Sci. 2017;60:575&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-016-9043-9</ArticleId><ArticleId IdType="pubmed">28547581</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh NJ, Lesi OA, Mendy M, Bah E, Akano A, Whittle H, et al. Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. Liver Int. 2011;31:215&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2010.02418.x</ArticleId><ArticleId IdType="pubmed">21143369</ArticleId></ArticleIdList></Reference><Reference><Citation>Mboto CI, Russell AD, Fielder M, Jewell AP. Hepatocellular Carcinoma in The Gambia and the role of Hepatitis B and Hepatitis C. Int Semin Surg Oncol. 2005;2:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7800-2-20</ArticleId></ArticleIdList></Reference><Reference><Citation>Diallo I, Ndiaye B, Tour&#xe9; M, Sow A, Mbengue A, Diawara PS, et al. Hepatocellular carcinoma in senegal&#x202f;: epidemiological, clinical and etiological aspects about 229 cases at H&#xf4;pital Principal de Dakar. Pan Afr Med J. 2021;38:99.</Citation><ArticleIdList><ArticleId IdType="doi">10.11604/pamj.2021.38.99.25195</ArticleId><ArticleId IdType="pubmed">33889265</ArticleId><ArticleId IdType="pmc">8035678</ArticleId></ArticleIdList></Reference><Reference><Citation>Tachi K, Nkansah AA, Archampong T. Hepatocellular carcinoma in Ghana: a retrospective analysis of a tertiary hospital data. Pan Afr Med J. 2020;36:43.</Citation><ArticleIdList><ArticleId IdType="doi">10.11604/pamj.2020.36.43.21085</ArticleId><ArticleId IdType="pubmed">32774619</ArticleId><ArticleId IdType="pmc">7388599</ArticleId></ArticleIdList></Reference><Reference><Citation>Davwar PM, Okeke E, Duguru M, Nyam D, Bell K, Odeghe EA, et al. Hepatocellular carcinoma presentation and prognosis among Nigerian adults with and without HIV. PLoS ONE. 2023;18:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0282539</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20:37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-022-00688-6</ArticleId><ArticleId IdType="pubmed">36258033</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut. 2014;63:844&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2013-306627</ArticleId><ArticleId IdType="pubmed">24531850</ArticleId></ArticleIdList></Reference><Reference><Citation>Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia hepatitis intervention study (1986&#x2013;90) and in the nationwide immunisation program. BMC Infect Dis. 2014;14:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-14-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittle HC, Inskip HI, Hall AJ, Mendy M, Downes R, Hoare S. Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia. Lancet Glob Heal. 1991;337:747&#x2013;50.</Citation></Reference><Reference><Citation>Mendy M, Peterson I, Hossin S, Peto T, Jobarteh M, Whittle H, et al. Observational study of vaccine efficacy 24 years after the start of hepatitis b vaccination in two Gambian villages&#x202f;: no need for a booster dose. PLoS. 2013;8:E58029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0058029</ArticleId></ArticleIdList></Reference><Reference><Citation>Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, et al. Hepatitis B vaccination in infancy in The Gambia&#x202f;: protection against carriage at 9 years of age. Vaccine. 1999;17:2946&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(99)00178-4</ArticleId><ArticleId IdType="pubmed">10462228</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Lv Y, Xu A, Wang H. The prognostic significance of serum gamma-glutamyltransferase levels and AST / ALT in primary hepatic carcinoma. BMC Cancer. 2019;19:841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-019-6011-8</ArticleId><ArticleId IdType="pubmed">31455253</ArticleId><ArticleId IdType="pmc">6712845</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrecker C, Waidmann O, El YH, Trojan J, Schnitzbauer AA, Bechstein WO, et al. Low platelet count predicts reduced survival in potentially resectable hepatocellular carcinoma. Curr Oncol. 2022;29:1475&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/curroncol29030124</ArticleId><ArticleId IdType="pubmed">35323324</ArticleId><ArticleId IdType="pmc">8947630</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wang R, Yang X. FIB-4 index serves as a noninvasive prognostic biomarker in patients with hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2018;97:e13696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000013696</ArticleId><ArticleId IdType="pubmed">30572498</ArticleId></ArticleIdList></Reference><Reference><Citation>Allenson K, Roife D, Kao LS, Ko TC, Wray CJ. Estimation of hepatocellular carcinoma mortality using aspartate aminotransferase to platelet ratio index. J Gastrointest Oncol. 2020;11:291&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jgo.2018.11.01</ArticleId><ArticleId IdType="pubmed">32399270</ArticleId><ArticleId IdType="pmc">7212111</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XY, Svn Z, Liv MS, Liu MN, Zhang YH, Sun Q. Assessment of prognostic value of aspartate aminotransferase-to-platelet ratio index in patients with hepatocellular carcinoma: meta-analysis of 28 cohort studies. Front Med. 2021;8:756210.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.756210</ArticleId></ArticleIdList></Reference><Reference><Citation>Koji U, Ryosuke T, Shuichiro S, Miho K, Ryota M, et al. Hepatocellular carcinoma with extrahepatic metastasis. Cancer. 2011;117:4475&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.25960</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekinci O, Baran B, Ormeci AC, Soyer OM, Gokturk S, Evirgen S, et al. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. World J Hepatol. 2018;10:51&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="doi">10.4254/wjh.v10.i1.51</ArticleId><ArticleId IdType="pubmed">29399278</ArticleId><ArticleId IdType="pmc">5787684</ArticleId></ArticleIdList></Reference><Reference><Citation>Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol. 2007;13:414&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v13.i3.414</ArticleId><ArticleId IdType="pubmed">17230611</ArticleId><ArticleId IdType="pmc">4065897</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JD, Mohamed EA, Abdelaziz AO, Shousha HI, Hashem MB, Nabeel MM, et al. Characteristics , management , and outcomes of patients with hepatocellular carcinoma in Africa&#x202f;: a multicountry observational study from the Africa Liver Consortium. Lancet Gastroenterol Hepatol. 2017;2:103&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(16)30161-3</ArticleId><ArticleId IdType="pubmed">28403980</ArticleId></ArticleIdList></Reference><Reference><Citation>Seid AS, Anugwom CM, Wondifraw Z, Braimoh GA, Bane A, Debes JD, et al. Single center analysis of therapy and outcomes of Hepatocellular carcinoma in Sub-Saharan Africa: an Ethiopian experience. Expert Rev Gastroenterol Hepatol. 2020;14:1007&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474124.2020.1802246</ArticleId><ArticleId IdType="pmc">7544626</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>